Items Tagged ‘zytiga’

February 23rd, 2015

Adding Zytiga to Prednisone Improves Survival and Pain in Chemotherapy-Naive Castration-Resistant Prostate Cancer Patients

By

The addition of Zytiga® (abiraterone acetate) to prednisone significantly improves survival of chemotherapy-naive patients whose prostate cancer has become resistant to hormone therapy.  Final results of the COU-AA-302 were reported in The Lancet Oncology and clear the way for a new treatment option for men with hormone refractory prostate cancer (HRPC).1 Prostate cancer is a […]

View full entry

Tags: abiraterone acetate, cancer, HRPC, Metastatic Stage IV (D) Prostate Cancer, new treatment option, News, prednisone, prostate, Prostate Cancer, Refactory/Recurrent Prostate Cancer, zytiga


June 18th, 2014

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer

By

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in metastatic prostate cancer patients who had been resistant to initial hormone therapy. Cells in the prostate gland have testosterone receptors and when […]

View full entry

Tags: hormone therapy, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi, zytiga